U.S. Consumer Durables Stock News

NYSE:EVC
NYSE:EVCMedia

Entravision Communications (EVC) Returns To Quarterly Profit In Q1 2026 Challenging Bearish Narratives

Entravision Communications (EVC) has opened 2026 with Q1 revenue of US$197.0 million and basic EPS of US$0.13, alongside net income from ongoing operations of US$12.4 million. The company has seen revenue move from US$91.9 million in Q1 2025 and US$107.0 million in Q4 2024 to US$197.0 million in Q1 2026. EPS has shifted from losses of US$0.53 and US$0.62 in those respective quarters to a profit in the latest period, setting up a quarter where investors will be focused on how durable these...
NYSE:BBAI
NYSE:BBAIIT

BigBear.ai Holdings (BBAI) Q1 Loss Of US$56.8 Million Reinforces Bearish Profitability Narrative

BigBear.ai Holdings (BBAI) opened Q1 2026 with revenue of about US$34.4 million and a basic EPS loss of roughly US$0.12, setting the tone for another quarter where growth and profitability are pulling in different directions. Over recent periods, revenue has moved between US$27.3 million and US$43.8 million a quarter, while basic EPS has ranged from a small profit of about US$0.01 to a loss of roughly US$0.71, underscoring how volatile margins have been as the business scales. In that...
NasdaqGS:ANGI
NasdaqGS:ANGIInteractive Media and Services

Angi (ANGI) Margin Improvement Supports Bullish Profitability Narrative Despite Modest FY 2025 Revenue

Angi (ANGI) posts FY 2025 results with steady profitability and modest top line Angi (ANGI) closed FY 2025 with fourth quarter revenue of US$240.8 million and basic EPS of US$0.17, while trailing twelve month EPS reached US$0.96 on net income of US$43.8 million, setting a clear reference point for the year at a share price of US$7.41. Over the past six reported quarters, revenue has ranged from US$240.8 million to US$296.7 million, while quarterly basic EPS has moved between a loss of US$0.03...
NasdaqGS:PHAT
NasdaqGS:PHATPharmaceuticals

A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline

Phathom Pharmaceuticals (PHAT) recently reported first quarter results showing a net loss of US$30.37 million, alongside reaffirmed 2026 guidance that includes an operating profitability target beginning in the third quarter. See our latest analysis for Phathom Pharmaceuticals. The stock’s recent 12.62% 1 month share price return, alongside a 7.56% 7 day gain, contrasts with a 19.35% year to date share price decline. At the same time, the 1 year total shareholder return above 400% highlights...
NYSE:HL
NYSE:HLMetals and Mining

Hecla Mining (HL) Q1 EPS Surge Tests Bullish Margin Narrative

Hecla Mining (HL) earnings snapshot Hecla Mining (HL) has put fresh numbers on the table for Q1 2026, with revenue of US$411.4 million, basic EPS of US$0.25 and net income from continuing operations of US$164.5 million, while also reporting earnings from discontinued operations of US$183.7 million. Over the past year, the company has seen revenue move from US$929.9 million on a trailing basis to US$1.57 billion and EPS shift from US$0.06 to US$0.69, alongside a very large year over year...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Lucid Group (LCID) Q4 Loss Of US$1.18b Tests Bullish Margin Improvement Narrative

Lucid Group (LCID) has just wrapped up FY 2025 with fourth quarter revenue of US$522.7 million, a basic EPS loss of US$3.62, and net income loss of US$1.18 billion. The trailing twelve month figures show revenue of US$1.35 billion and a basic EPS loss of US$11.81. The company’s revenue has moved from US$807.8 million on a trailing basis at the end of 2024 to US$1.35 billion by the end of 2025. EPS has remained deeply negative over the same stretch, setting up a results season in which...
NYSE:AIZ
NYSE:AIZInsurance

Assurant (AIZ) Q1 EPS Beat Strength Narrative Of Margin Stability And Earnings Quality

Assurant (AIZ) kicked off 2026 with Q1 revenue of US$3.4 billion and basic EPS of US$5.51, alongside net income excluding extra items of US$274.1 million, setting a clear marker for how the year is starting to shape up. Over recent quarters the company has seen revenue move from US$3.1 billion in Q1 2025 to US$3.4 billion in Q1 2026. Basic EPS has ranged between US$2.86 and US$5.23 in 2025 before reaching US$5.51 this quarter, giving you a clear view of how the income line has been tracking...
NYSE:JXN
NYSE:JXNDiversified Financial

Jackson Financial Q1 EPS Loss Deepens Challenging Bullish Margin Narratives

Jackson Financial's Q1 2026 Numbers Set the Stage for a Margin Story Jackson Financial (JXN) has opened 2026 with Q1 revenue of about US$2.9 billion and a basic EPS loss of US$6.24, alongside a trailing twelve month EPS loss of US$5.94 and net income loss of US$417 million. The company has seen quarterly revenue range from US$245 million in Q4 2024 to US$3.8 billion in Q1 2025. Basic EPS has swung between a profit of US$4.50 in Q4 2024 and the current Q1 2026 loss, which puts investor...
NasdaqGS:AZTA
NasdaqGS:AZTALife Sciences

Azenta (AZTA) Quarterly Loss Of US$157 Million Reinforces Bearish Margin Narratives

Azenta (AZTA) has put a tough quarter on the table, with Q2 2026 revenue of US$144.8 million and a basic EPS loss of US$3.41, alongside net income from continuing operations showing a loss of US$157.0 million. The company has seen quarterly revenue move from US$143.4 million in Q2 2025 to US$158.0 million in Q4 2025 and then to US$144.8 million in Q2 2026. EPS has swung from a loss of US$0.40 in Q2 2025 to a profit of US$1.12 in Q4 2025 and back to a loss of US$3.41 in the latest quarter,...
NasdaqGS:RIGL
NasdaqGS:RIGLBiotechs

Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High‑Earnings Narrative

Rigel Pharmaceuticals (RIGL) opened 2026 with Q1 revenue of US$58.8 million and basic EPS of US$0.47, alongside trailing 12‑month revenue of US$299.8 million and basic EPS of US$20.08, set against very large year over year earnings growth and higher net profit margins in the latest trailing figures. Over recent quarters the company has seen revenue move from US$57.6 million in Q4 2024 to US$53.3 million in Q1 2025, US$101.7 million in Q2 2025, US$69.5 million in Q3 2025 and US$69.8 million in...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Duolingo (DUOL) Q1 Margin Strength Tests Bullish Profit Sustainability Narratives

Q1 2026 earnings snapshot Duolingo (DUOL) opened 2026 with Q1 revenue of US$292.0 million and basic EPS of US$0.93, setting the tone for the latest results at a share price of US$105.02. Over the past year, the company has seen revenue move from US$230.7 million in Q1 2025 to US$292.0 million in Q1 2026, while basic EPS shifted from US$0.78 to US$0.93, against a trailing twelve month EPS figure of US$9.14. With trailing net profit margins now framed by a much higher earnings base, the story...
NYSE:MCY
NYSE:MCYInsurance

Mercury General (MCY) Wildfire Combined Ratio Swings Challenge Underwriting Stability Narratives

Mercury General (MCY) closed out FY 2025 with Q4 revenue of US$1.5 billion and basic EPS of US$3.66, supported by trailing twelve month revenue of US$6.0 billion and EPS of US$9.77. Over the past few quarters, revenue has moved from US$1.39 billion in Q1 2025 to US$1.54 billion in Q4 2025, while quarterly EPS has ranged from a loss of US$1.96 in Q1 2025 to a high of US$5.06 in Q3 2025. These figures provide context for investors assessing recent net income of US$202.5 million alongside a more...
NYSE:STWD
NYSE:STWDMortgage REITs

What Starwood Property Trust (STWD)'s FIP Acquisition and Dilution Concerns Mean For Shareholders

In recent days, analyst reports from JPMorgan and BofA Securities reassessed Starwood Property Trust following its Fundamental Income Partners acquisition and ongoing sector headwinds in commercial real estate finance. While highlighting higher interest rates and potential dilution as near-term challenges, the commentary also underscored that Starwood’s lending pipeline and capital deployment activity remain meaningfully engaged, keeping institutional attention on the REIT. Next, we’ll...
NYSE:LDOS
NYSE:LDOSProfessional Services

Leidos Holdings (LDOS) Net Margin Near 8.2% Tests Slower Earnings Growth Narratives

Leidos Holdings (LDOS) opened 2026 with Q1 revenue of US$4.4b and basic EPS of US$2.60, alongside trailing 12 month revenue of US$17.3b and EPS of US$11.13 that sit against a 8.2% net margin, up from 7.9% a year earlier. Over the past year, earnings growth of 6.1% has run below the five year average of 18.1%. This puts more weight on how investors read the balance between steady profit generation and the current margin profile. Overall, the latest numbers point to a business where...
NasdaqCM:NUTX
NasdaqCM:NUTXHealthcare

Nutex Health (NUTX) Is Up 5.1% After Strong Q1 Results And New Buyback Plan - What's Changed

Nutex Health reported past first-quarter 2026 results on April 30, with revenue of US$216.49 million and net income of US$46.81 million, lifting both basic and diluted earnings per share from continuing operations versus a year earlier. Alongside these results, the company announced a second US$25.00 million share repurchase program and a shift toward directly developing new hospital facilities, signaling a material change in how it funds and expands its footprint. We’ll now examine how...
NYSE:AU
NYSE:AUMetals and Mining

Is It Too Late To Consider AngloGold Ashanti (NYSE:AU) After 136% One Year Surge?

Wondering whether AngloGold Ashanti at around US$98.60 is still offering value after a strong run, or if most of the easy gains are already behind it. The stock has been volatile recently, with a 9.0% return over the last 7 days, a 2.8% decline over 30 days, a 15.2% return year to date, and a 136.0% return over the last year, alongside very large multi year gains of around 3x over 3 years and nearly 4x over 5 years. Recent coverage has focused on AngloGold Ashanti's position within the...
NYSE:FERG
NYSE:FERGTrade Distributors

Ferguson (FERG) Q1 2026 Margin Gains Test Bullish Earnings Narratives

Ferguson Enterprises Q1 2026 headline numbers Ferguson Enterprises (FERG) opened fiscal Q1 2026 with revenue of about US$7.5b and basic EPS of US$2.13, setting a clear marker for how the business is starting the new financial year. The company has seen quarterly revenue move from roughly US$7.2b in Q1 2025 to about US$7.5b in Q4 2025 and then US$7.5b in Q1 2026. Basic EPS has shifted from US$1.74 to US$1.99 and then US$2.13 over the same periods, giving investors a view on how earnings are...
NYSE:JBTM
NYSE:JBTMMachinery

JBT Marel (JBTM) Quarterly Profit Of US$53.1m Tests Bearish Loss-Narrative

JBT Marel (JBTM) has just put fresh numbers on the table for Q1 2026, coming off Q4 2025 revenue of about US$1.0 billion and basic EPS of US$1.02, against a trailing twelve month picture that includes a basic EPS loss of US$0.96 on US$3.8 billion of revenue. Over the past few quarters, the company has seen quarterly revenue move from US$453.8 million in Q3 2024 to US$854.1 million in Q1 2025 and then to roughly US$1.0 billion by Q4 2025. EPS swung from US$1.19 in Q3 2024 to a loss of US$3.35...
NYSE:NRG
NYSE:NRGElectric Utilities

Is It Time To Revisit NRG Energy (NRG) After Its Strong Five Year Share Price Gain

With NRG Energy last closing at US$150.64, this article looks at whether the stock is still priced for opportunity or already reflects most of its story, and what that may mean for you as an investor. The stock has returned 1.1% over the last 7 days and 0.6% over the last 30 days, with a year-to-date decline of 9.3% and a 28.4% return over the last year, alongside a very large gain over 5 years. Recent coverage has focused on NRG Energy's position within the US utilities sector and how its...
NYSE:VG
NYSE:VGOil and Gas

Venture Global’s CP2 Progress And New Deals Reshape Risk Reward Profile

Venture Global (NYSE:VG) has taken a final investment decision on Phase 2 of its CP2 LNG project and secured project financing, reducing construction and cash flow risks. The company reached a commercial settlement with Edison related to Calcasieu Pass arbitration, addressing an outstanding legal dispute. Venture Global signed a new binding LNG purchase agreement with Vitol for five years starting in 2026. For investors watching US LNG developers, Venture Global sits at the intersection of...
NYSE:FND
NYSE:FNDSpecialty Retail

Is It Time To Reconsider Floor & Decor (FND) After A 30% One Year Share Price Drop

If you are wondering whether Floor & Decor Holdings at around US$51 a share is attractively priced or a potential value trap, the starting point is understanding how the current market price lines up against different measures of value. The stock has recently moved 7.0% over the last week and 3.3% over the last month, while the year to date return sits at a 19.0% decline and the 1 year return at a 30.5% decline, which may catch the eye of investors weighing up risk and recovery...
NYSE:IT
NYSE:ITIT

Gartner (IT) Margin Reset To 11.2% Reinforces Bearish Profitability Narratives

Gartner (IT) has put fresh numbers on the board for Q1 2026, reporting revenue of US$1.5b and basic EPS of US$3.19 off net income of US$222.3m, setting the tone for how you might think about the rest of the year. Over recent quarters the company has seen revenue move between US$1.5b and US$1.8b, while quarterly EPS has ranged from US$0.47 to US$5.14, providing a clear view of how earnings power has fluctuated into this latest print. With trailing net margins now sitting well below last year’s...
NYSE:SMR
NYSE:SMRElectrical

Is NuScale Power (SMR) Pricing In Nuclear Policy Support Despite Mixed Long Term Returns

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...
NasdaqGS:GH
NasdaqGS:GHHealthcare

FDA Approval Adds New Catalyst To Guardant Health Valuation Story

Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations. This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments. The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners. For investors tracking Guardant Health...